2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1)
申请人:Brown Rebecca Elizabeth
公开号:US20090298856A1
公开(公告)日:2009-12-03
The use of a compound of formula (I): for the manufacture of a medicament for the treatment of conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1, also known as TRPV1).
2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES MODULATING THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1)
申请人:MERCK SHARP & DOHME LTD.
公开号:EP1881988A1
公开(公告)日:2008-01-30
[EN] 2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES MODULATING THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1)<br/>[FR] PYRIMIDINE-4(3H)-ONES BICYCLIQUES FUSIONNEES SUBSTITUEES EN 2,3 MODULANT LA FONCTION DU RECEPTEUR VANILLOIDE-1 (VR1)
申请人:MERCK SHARP & DOHME
公开号:WO2006122200A1
公开(公告)日:2006-11-16
[EN] The use of a compound of formula (I): for the manufacture of a medicament for the treatment of conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1, also known as TRPV1). [FR] Utilisation d'un composé de formule (I): pour la fabrication d'un médicament pour le traitement d'états améliorés par la modulation de la fonction du récepteur vanilloïde-1 (VR1, aussi connu sous le nom de TRPV1).
[EN] CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF<br/>[FR] INHIBITEURS DE CD73 ET LEURS UTILISATIONS PHARMACEUTIQUES
申请人:[en]RISEN (SUZHOU) PHARMA TECH CO., LTD.
公开号:WO2022109741A1
公开(公告)日:2022-06-02
CD73 (also known as ecto-5´-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune-related disorders. CD73 inhibitor compounds include compounds having the structure set forth in Formula I': (I') and pharmaceutically acceptable esters or salts thereof.